echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Policy "combo" has been launched one after another, and enterprises have laid out research and development of anti-cancer drugs

    Policy "combo" has been launched one after another, and enterprises have laid out research and development of anti-cancer drugs

    • Last Update: 2019-10-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] with the population growth and the improvement of the aging level of the population, cancer patients in China are on the increase trend, driving the sustained growth of the anti-cancer drug market According to some data, the scale of cancer in China has reached 126.819 billion yuan in 2017, with an average compound growth rate of 12.30% in the past five years It is estimated that the scale of cancer drug market in China will reach 180-220 billion yuan in 2020-2022 In the face of the huge drug market, domestic pharmaceutical companies have begun to accelerate the research and development process of anticancer drugs Recently, it has been announced that carrizumab for Hengrui injection will be included in the priority review According to the previous announcement, the indications included in the priority review should be the first-line treatment of advanced esophageal squamous cell carcinoma with carrizumab and the first-line treatment of advanced or metastatic non-small cell lung cancer with pemetrexed and carboplatin The policy of anti-cancer drugs has been issued constantly Although more and more drug companies are developing anti-cancer drugs, it is well known that anti-cancer drugs are expensive, and many patients still cannot afford to use them In order to solve this problem, a series of policies of "combination boxing" in our country are making efforts in succession On April 23, 2018, the state issued a notice to reduce the import tariff of drugs Since May 1, 2018, China has reduced the import tariff of 28 drugs, including anti-cancer drugs, from the original 3% - 6% to zero In July, the "technical guidelines for accepting overseas clinical trial data of drugs" was issued, which recognized that the data of overseas clinical trials of drugs, bioequivalence experiments of generic drugs and overseas clinical trials of biological similar drugs that met the requirements, and the approval of imported drugs was accelerated On October 10, 2018, the national health insurance bureau announced that 17 kinds of anti-cancer drugs will be included in the medical insurance Most of the imported drugs will be paid at a lower price than the market price of the surrounding countries or regions after negotiation, further reducing the drug burden of cancer patients in China   In 2019, China will further strengthen the protection of cancer prevention and treatment drugs For example, after the pilot procurement with volume, 25 selected products will start to reduce prices by a large margin, with an average price reduction of 52%, and the price reduction of anti-cancer drugs by more than 95%; on August 20, the 2019 version of the national health insurance regular catalog was released, and some drugs for treatment of major diseases such as cancer and rare diseases will enter the list of proposed negotiations, and enter the catalog after negotiation 。 The new version of the catalogue will be officially implemented on January 1, 2020   On September 23, the notice on printing and distributing health China action - cancer prevention and control implementation plan (2019-2022) issued by the Ministry of health of the people's Republic of China mentioned the establishment of cancer regional medical center, the improvement of the accessibility of anti-cancer drugs, and the strengthening of the unique role of traditional Chinese medicine in cancer prevention and control It is required that by 2022, the overall 5-year survival rate of cancer will be increased by 3 percentage points compared with that in 2015, and the disease burden of patients will be increased To effective control In the face of the broad market demand and the continuous favorable policies, domestic enterprises have vigorously carried out the research and development of anti-cancer drugs Prior to that, the new nano anticancer drug cpi-100 developed by CPI (coordination pharmaceuticals, Inc.), a joint-stock company of Kunming Pharmaceutical Group, was approved by the US Food and Drug Administration (FDA), and will carry out phase I clinical trials for patients with advanced colorectal cancer, esophageal cancer and other solid tumors in the near future The implementation of the project indicates the new breakthrough of Kunming Pharmaceutical in the development of innovative drugs for cancer treatment, and will further promote the innovation ability of the company In recent years, Sinopharm group has not only increased the research and development of tumor drugs, but also actively looked for cooperation and acquisition opportunities Among them, we signed an agreement with verastema company in the United States to obtain the authorization for the development and commercialization of the cancer drug copiktra During the reporting period, the sales revenue of cancer medicine series of Shiyao group increased by 123.3% In addition, according to the first quarter performance report issued by Sinopharm group in May this year, copiktra's listing application in China has been accepted, and it is expected to be approved for listing in 2021 As the leading enterprise of anti-tumor drugs in China, Hengrui medicine has obvious R & D and marketing advantages in the field of anti-tumor drugs Many of its drugs are in NDA application and clinical phase III, covering lung cancer, breast cancer, gastric cancer, diabetes and other diseases in the current hot market The network includes many hot targets such as PD-L1 and CDK4 / 6 In general, the market prospect of anticancer drugs in China is good In this context, more and more domestic enterprises have begun to join in the research and development of innovative drugs such as anti-tumor drugs For example, Fosun Pharmaceutical, Beida pharmaceutical, Kelun pharmaceutical, Shanghai pharmaceutical, etc., and some pharmaceutical companies have made some breakthroughs in anti-cancer drugs Although, the R & D capacity of Chinese anticancer drugs is relatively weak at present, and the road of R & D is still blocked and long However, with the development of new drugs in China, more and more anti-cancer drugs will be given good news in the future, which will further benefit cancer patients in China and reduce the burden of drug use!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.